破裂性胸主动脉瘤TEVAR术后并发症仍高于择期修复
基于VQI登记2010-2020年3039例胸主动脉瘤TEVAR患者,比较破裂与完整动脉瘤修复。破裂者围术期死亡27% vs 4.6%,5年生存50% vs 76%。既往主动脉修复、吸烟史及术前β受体阻滞剂或他汀治疗与破裂风险降低相关。
要点
- 破裂性胸主动脉瘤TEVAR围术期死亡率27%,显著高于完整动脉瘤的4.6%。
- 破裂者5年生存率50%,低于完整动脉瘤的76%。
- 既往主动脉修复、吸烟史及术前β受体阻滞剂或他汀治疗与破裂风险降低相关。
核心结论
- 破裂性胸主动脉瘤TEVAR的围术期死亡率和并发症高于完整动脉瘤,5年生存率更低。
- 既往主动脉修复、吸烟史及术前β受体阻滞剂或他汀治疗与破裂风险降低相关。
研究设计与样本
- 回顾性队列研究,查询VQI登记2010-2020年,纳入3039例胸主动脉瘤TEVAR患者,其中完整动脉瘤2806例(92%),破裂动脉瘤233例(8%)。
主要发现
- 慢性肾病与破裂风险增加相关(OR 3.1,95%CI 2.0-4.9,P < .001)。
- 既往主动脉修复(OR 0.71,95%CI 0.49-0.97,P = .05)、既往吸烟(OR 0.36,95%CI 0.24-0.53,P < .001)、术前β受体阻滞剂(OR 0.57,95%CI 0.41-0.80,P = .001)及术前他汀(OR 0.68,95%CI 0.49-0.94,P = .020)与破裂风险降低相关。
- 破裂vs完整动脉瘤围术期死亡率27% vs 4.6%(OR 6.6,95%CI 4.3-10,P < .001)。
- 复合终点(死亡、新透析、截瘫、卒中)38% vs 9.5%(OR 5.1,95%CI 3.5-7.4,P < .001)。
- 5年生存率破裂组50% vs 完整组76%(P < .001;HR 0.39,95%CI 0.29-0.52,P < .001);术前他汀与5年生存率提高相关(HR 1.3,95%CI 1.0-1.6,P = .021)。
临床怎么用
- 对胸主动脉瘤患者应重视术前β受体阻滞剂和他汀治疗,可能降低破裂风险并改善生存。
- 破裂性胸主动脉瘤TEVAR围术期风险和远期死亡风险高,需充分知情和围术期管理。
局限性
- 回顾性登记研究,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) for ruptured thoracic aortic aneurysms is associated with increased perioperative mortality and morbidity compared with intact repair. The purpose of our study was to evaluate the factors associated with the presentation of ruptured aneurysms and adverse outcomes after repair. METHODS: The Vascular Quality Initiative (VQI) registry was queried (2010-2020) to identify patients who had undergone TEVAR for ruptured and intact thoracic aortic aneurysms. The primary outcome was to identify the factors associated with ruptured thoracic aortic aneurysms. The secondary outcomes included perioperative mortality and morbidity, 5-year survival, and the identification of factors associated with adverse outcomes after TEVAR. RESULTS: Of the 3039 patients identified with a thoracic aortic aneurysm, 2806 (92%) had undergone repair for an intact aneurysm and 233 (8%) had undergone repair for a ruptured aneurysm. Chronic kidney disease was associated with a greater odds of a presentation with a ruptured aneurysm (odds ratio [OR], 3.1; 95% confidence interval [CI], 2.0-4.9; P < .001). The factors associated with a lower odds of rupture included prior aortic aneurysm repair (OR, 0.71; 95% CI, 0.49-0.97; P = .05), prior smoker (OR, 0.36; 95% CI, 0.24-0.53; P < .001), preoperative beta-blocker therapy (OR, 0.57; 95% CI, 0.41-0.80; P = .001), and preoperative statin therapy (OR, 0.68; 95% CI, 0.49-0.94; P = .020). TEVAR for ruptured thoracic aortic aneurysms was associated with higher perioperative mortality (rupture vs intact, 27% vs 4.6%; OR, 6.6; 95% CI 4.3-10; P < .001) and the composite outcome of mortality, new dialysis, paralysis, and stroke (38% vs 9.5%; OR, 5.1; 95% CI, 3.5-7.4; P < .001). The 5-year survival was significantly lower after TEVAR for ruptured thoracic aortic aneurysms (50% vs 76%; P < .001; hazard ratio, 0.39; 95% CI, 0.29-0.52; P < .001). Preoperative statin therapy was associated with higher 5-year survival (hazard ratio, 1.3; 95% CI, 1.0-1.6; P = .021). CONCLUSIONS: TEVAR for ruptured thoracic aortic aneurysms results in increased perioperative mortality and morbidity and lower 5-year survival compared with TEVAR for intact aneurysms. Patients with prior aortic aneurysm repair, prior smoking, and preoperative beta-blocker or statin therapy were less likely to present with ruptured thoracic aneurysms. This correlation might be attributed to increased exposure to cardiovascular healthcare providers and, thus, subsequently increased screening and surveillance, allowing for elective repair of thoracic aortic aneurysms.
引用
- Patel PB, Marcaccio CL, de Guerre LEVM, et al. Complications after thoracic endovascular aortic repair for ruptured thoracic aortic aneurysms remain high compared with elective repair. J Vasc Surg. 2021. PMID: 34655686. doi:10.1016/j.jvs.2021.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。